Zydus Cadila gains on signing strategic collaboration agreement with Eczactbast hag Pazarlama

15 Jun 2016 Evaluate

Cadila Healthcare is currently trading at Rs. 321.00, up by 1.90 points or 0.60% from its previous closing of Rs. 319.10 on the BSE.

The scrip opened at Rs. 318.60 and has touched a high and low of Rs. 322.15 and Rs. 318.60 respectively. So far 28307 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 454.40 on 23-Oct-2015 and a 52 week low of Rs. 295.50 on 18-Jan-2016.

Last one week high and low of the scrip stood at Rs. 322.00 and Rs. 315.00 respectively. The current market cap of the company is Rs. 32759.76 crore.

The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 13.85% and 11.36% respectively.

Zydus Cadila has signed a strategic collaboration agreement with Eczactbast hag Pazarlama A.S., a leading healthcare company of Turkey to market biotech products in the Turkish market. The agreement involves the import of biosimilars which are currently unavailable in the country especially for the treatment of cancer and it also paves the way for a long term strategic collaboration to produce and launch new products in the market.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

867.80 -16.20 (-1.83%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×